SUNScholar will be unavailable on 25 April 2018 from 08:00 to 10:00 South African Time for routine maintenance. Please contact for queries.

The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection

Pretorius E. ; Klinker H. ; Rosenkranz B. (2011)


Therapeutic drug monitoring (TDM) is a well-established method to optimize dosing regimens in individual patients for drugs that are characterized by a narrow therapeutic range and large interindividual pharmacokinetic variability. For some antiretroviral drugs, mainly nonnucleoside reverse transcriptase inhibitors and protease inhibitors, TDM has been proposed as a means to improve the response in human immunodeficiency virus-infected patients. In contrast, nucleoside reverse transcriptase inhibitors do not show a predictable plasma concentration-response (toxicity, efficacy) relationship, and intracellular analyses are expensive. Therefore, TDM is generally not recommended for this class of drugs. TDM has been successfully applied in the clinical practice for certain antiretroviral drugs, but there are ongoing research efforts on the use and refinement of TDM for human immunodeficiency virus treatment, and convincing data from randomized trials are still needed. The best pharmacokinetic measures of drug exposure such as trough and peak concentrations or concentration ratios have not been unambiguously established. Copyright © 2011 by Lippincott Williams & Wilkins.

Please refer to this item in SUNScholar by using the following persistent URL:
This item appears in the following collections: